Skip to content

Philippe Marin

5 papers in the library · 163 citations · publishing 2014-2025

Papers

Sort Most recent Most cited

A reciprocal interplay between 5-HT2A and mGlu5 receptors underlies neuroplasticity

bioRxiv Preprint Server July 23, 2025 Tomas Del Olmo, Mathilde Decourcelle, Martial Séveno et al. preprint

The serotonin (5-HT)2A receptor is the primary target of numerous psychoactive drugs including serotonergic psychedelics, and mediates psychedelics-induced neuroplasticity, but the signaling mechanisms involved remain poorly characterized. Using quantitative phosphoproteomics, we show that the administration of the hallucinogenic 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) to...

Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT2A receptor activation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie June 17, 2024 Hugo R Arias, L. Micheli, Deborah Rudin et al. 14 citations

The aim of this study was to determine the anti-hypersensitivity activity of novel non-hallucinogenic compounds derived from iboga alkaloids (i.e., ibogalogs), including tabernanthalog (TBG), ibogainalog (IBG), and ibogaminalog (DM506), using mouse models of neuropathic (Chronic Constriction Injury; CCI) and visceral pain (dextrane sulfate sodium; DSS). Ibogalogs decreased mechanical...

Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology March 1, 2024 Mehdi Sekssaoui, Joël Bockaert, Philippe Marin et al. 76 citations

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the...

Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 1, 2022 Błażej D. Pędzich, Sarah Rubens, Mehdi Sekssaoui et al.

Psychedelic-assisted psychotherapy gained considerable interest as a novel treatment strategy for fear-related mental disorders but the underlying mechanism remains poorly understood. The serotonin 2A (5-HT2A) receptor is a key target underlying the effects of psychedelics on emotional arousal but its role in fear processing remains controversial. Using the psychedelic 5-HT2A/5-HT2C receptor...

Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Nonhallucinogenic Agonists

Molecular & Cellular Proteomics March 18, 2014 Samah Karaki, Carine Bécamel, Samy Murat et al. 73 citations

The serotonin 5-HT(2A) receptor is a primary target of psychedelic hallucinogens such as lysergic acid diethylamine, mescaline, and psilocybin, which reproduce some of the core symptoms of schizophrenia. An incompletely resolved paradox is that only some 5-HT(2A) receptor agonists exhibit hallucinogenic activity, whereas structurally related agonists with comparable affinity and activity lack...